July 18 - A Reuters analysis finds the largest shareholders of biotechs bought into the companies at such low costs, they'll likely be willing sellers in a takeover bid and could make billions in profits.
This summer it's been more about by. Biotech side people are chasing a little rest right now which I never -- not a Biotech investor but you can't deny that people are chasing them. Positions. In six of the eight companies that we look back. Shift toward this I'm a much lower cost basis -- win a chance of turning now. Of course the chance to have kind of compliment you know difficult situation I'm tickled -- the show whether there's already in the money. And the likelihood that -- -- itself would be -- -- of setting. Increases. This is just one data point and -- when you look I have these six by -- it by the company's. And one of them Exelixis. Question or across was actually higher than that the stock is trading -- now which sort of presents an interesting opportunity. Especially if you're an -- but it is different that's pieces there would be that somebody would come and -- it. Or it and -- buy it and the issue or those wanna be positioned mind. And I stress might want to make a premium and.